African sleeping sicknesss - Eflornithine should be the drug of choice for stage 2 disease, but resistance must be monitored

Checchi, F. and Barrett, M.P. (2008) African sleeping sicknesss - Eflornithine should be the drug of choice for stage 2 disease, but resistance must be monitored. British Medical Journal, 336(7646), pp. 679-680. (doi:10.1136/bmj.39505.490544.BE)

Checchi, F. and Barrett, M.P. (2008) African sleeping sicknesss - Eflornithine should be the drug of choice for stage 2 disease, but resistance must be monitored. British Medical Journal, 336(7646), pp. 679-680. (doi:10.1136/bmj.39505.490544.BE)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1136/bmj.39505.490544.BE

Abstract

When human African trypanosomiasis (sleeping sickness) killed millions of people during Africa's colonial period 60-100 years ago, interest was similar to that for today's HIV epidemic, but the disease is now largely forgotten. The continuing importance of this disease is highlighted in the accompanying paper by Priotto and colleagues, who report the effectiveness and safety of eflornithine used for its first line treatment.

Item Type:Articles
Status:Published
Refereed:No
Glasgow Author(s) Enlighten ID:Barrett, Professor Michael
Authors: Checchi, F., and Barrett, M.P.
Subjects:R Medicine > RA Public aspects of medicine
R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:British Medical Journal
Journal Abbr.:BMJ
Publisher:BMJ Publishing Group
ISSN:0959-535X
ISSN (Online):1756-1833
Copyright Holders:Copyright © 2008 BMJ Publishing Group
First Published:First published in British Medical Journal 336(7646):679-680
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record